MIAMI, FL -- (MARKET WIRE) -- November 15, 2006 -- DOR BioPharma, Inc. (OTCBB: DORB) (“DOR” or “the Company”) announced today that the Company has made advancements in the long-term stability and optimization of the formulation of RiVax™, a vaccine that contains a recombinant subunit of the A chain of ricin toxin and has been shown to induce ricin neutralizing antibodies in humans and animals. An article characterizing the conditions for maintaining long-term stability of RiVax™ has been published online in advance of print publication in the Journal of Pharmaceutical Science.
